ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization

Journal of Immunology

Volumn 184, Issue 6, 2010, Pages 2776-2784

  Hasselberg, Annemarie ^a   Ekman, Lena ^a   Yrlid, Linda Fahlén ^a   Schön, Karin ^a   Lycke, Nils Y ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CHOLERA TOXIN; IMMUNOGLOBULIN A; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; HYBRID PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OVA 323 339; OVA 323-339; OVALBUMIN; PEPTIDE FRAGMENT;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; BAGG ALBINO MOUSE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SPLEEN CELL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; GENETICS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NOSE MUCOSA; NUDE MOUSE; PHYSIOLOGY; TRANSGENIC MOUSE;

ADMINISTRATION, INTRANASAL; ADP RIBOSE TRANSFERASES; ANIMALS; CELLS, CULTURED; FEMALE; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; NASAL MUCOSA; OVALBUMIN; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 77951887579     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901445     Document Type: Article

References (60)

1. Faria, A. M., and H. L. Weiner. 2005. Oral tolerance. Immunol. Rev. 206: 232-259.
2. Mowat, A. M. 2003. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 3: 331-341.
3. Ryan, E. J., L. M. Daly, and K. H. Mills. 2001. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19: 293-304.
4. Neutra, M. R., and P. A. Kozlowski. 2006. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6: 148-158.
5. Rolland, J. M., L. M. Gardner, and R. E. O'Hehir. 2009. Allergen-related approaches to immunotherapy. Pharmacol. Ther. 121: 273-284.
6. Mestecky, J., M. W. Russell, and C. O. Elson. 2007. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179: 5633-5638.
7. O'Hehir, R. E., A. Sandrini, G. P. Anderson, and J. M. Rolland. 2007. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr. Med. Chem. 14: 2235-2244.
8. Samsom, J. N. 2004. Regulation of antigen-specific regulatory T-cell induction via nasal and oral mucosa. Crit. Rev. Immunol. 24: 157-177.
9. Faria, A. M., and H. L.Weiner. 2006. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13: 143-157.
10. Strober, W. 2008. Vitamin A rewrites the ABCs of oral tolerance. Mucosal Immunol. 1: 92-95.
11. Hintzen, G., L. Ohl, M. L. del Rio, J. I. Rodriguez-Barbosa, O. Pabst, J. R. Kocks, J. Krege, S. Hardtke, and R. Förster. 2006. Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node. J. Immunol. 177: 7346-7354. (Pubitemid 44715105)
12. Lavelle, E. C., A. Jarnicki, E. McNeela, M. E. Armstrong, S. C. Higgins, O. Leavy, and K. H. Mills. 2004. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 75: 756-763.
13. Lycke, N. 2007. Mechanisms of adjuvant action. In Vaccine Adjuvants and Delivery Systems. M. Singh, ed. Wiley, Hoboken, New Jersey.
14. Yamamoto, M., H. Kiyono, M. N. Kweon, S. Yamamoto, K. Fujihashi, H. Kurazono, K. Imaoka, H. Bluethmann, I. Takahashi, Y. Takeda, et al. 2000. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses. J. Infect. Dis. 182: 180-190.
15. D'Ambrosio, A., M. Colucci, O. Pugliese, F. Quintieri, and M. Boirivant. 2008. Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation. J. Leukoc. Biol. 84: 661-668.
16. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat. Med. 11(4): Suppl): S45-S53.
17. Williams, N. A., T. R. Hirst, and T. O. Nashar. 1999. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol. Today 20: 95-101.
18. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187: 1123-1132.
19. Hagiwara, Y., Y. I. Kawamura, K. Kataoka, B. Rahima, R. J. Jackson, K. Komase, T. Dohi, P. N. Boyaka, Y. Takeda, H. Kiyono, et al. 2006. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J. Immunol. 177: 3045-3054. (Pubitemid 44277821)
20. Agren, L. C., L. Ekman, B. Löwenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158: 3936-3946.
21. Agren, L. C., L. Ekman, B. Löwenadler, J. G. Nedrud, and N. Y. Lycke. 1999. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162: 2432-2440.
22. Akhiani, A. A., A. Stensson, K. Schön, and N. Lycke. 2006. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand. J. Immunol. 63: 97-105.
23. Eliasson, D. G., K. El Bakkouri, K. Schön, A. Ramne, E. Festjens, B. Löwenadler, W. Fiers, X. Saelens, and N. Lycke. 2008. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-1252.
24. Eriksson, A. M., K. M. Schön, and N. Y. Lycke. 2004. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173: 3310-3319.
25. van Ginkel, F. W., R. J. Jackson, Y. Yuki, and J. R. McGhee. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165: 4778-4782.
26. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180: 25-34.
27. Kühn, R., J. Löhler, D. Rennick, K. Rajewsky, and W. Müller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274. (Pubitemid 23320290)
28. Murphy, K. M., A. B. Heimberger, and D. Y. Loh. 1990. Induction by antigen of intrathymic apoptosis ofCD4+CD8+TCRlo thymocytes in vivo. Science 250: 1720-1723.
29. Grdic, D., L. Ekman, K. Schön, K. Lindgren, J. Mattsson, K. E. Magnusson, P. Ricciardi-Castagnoli, and N. Lycke. 2005. Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin. J. Immunol. 175: 5192-5202. (Pubitemid 41456404)
30. + T helper cell phenotype development in a T cell receptor-αβ-transgenic model. J. Exp. Med. 182: 1579-1584.
31. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
32. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212: 28-50.
33. Henry, E., C. J. Desmet, V. Garzé, L. Fiévez, D. Bedoret, C. Heirman, P. Faisca, F. J. Jaspar, P. Gosset, A. P. Jacquet, et al. 2008. Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J. Immunol. 181: 7230-7242.
34. Rynda, A., M. Maddaloni, D. Mierzejewska, J. Ochoa-Repáraz, T. Maslanka, K. Crist, C. Riccardi, B. Barszczewska, K. Fujihashi, J. R. McGhee, and D. W. Pascual. 2008. Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J. Immunol. 180: 5187-5200.
35. Maynard, C. L., and C. T.Weaver. 2008. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol. Rev. 226: 219-233.
36. Maynard, C. L., L. E. Harrington, K. M. Janowski, J. R. Oliver, C. L. Zindl, A. Y. Rudensky, and C. T. Weaver. 2007. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat. Immunol. 8: 931-941.
37. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, and M. G. Roncarolo. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742. (Pubitemid 27458961)
38. Zheng, S. G., J. H.Wang, J. D. Gray, H. Soucier, and D. A. Horwitz. 2004. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J. Immunol. 172: 5213-5221.
39. Mosser, D. M., and X. Zhang. 2008. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226: 205-218.
40. Murray, P. J. 2006. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 6: 379-386.
41. Cheng, F., H. W. Wang, A. Cuenca, M. Huang, T. Ghansah, J. Brayer, W. G. Kerr, K. Takeda, S. Akira, S. P. Schoenberger, et al. 2003. A critical role for Stat3 signaling in immune tolerance. Immunity 19: 425-436.
42. O'Garra, A., and P. Vieira. 2007. T(H)1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7: 425-428.
43. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174: 915-924.
44. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815-3822.
45. Ding, L., P. S. Linsley, L. Y. Huang, R. N. Germain, and E. M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151: 1224-1234.
46. Taga, K., H. Mostowski, and G. Tosato. 1993. Human interleukin-10 can directly inhibit T-cell growth. Blood 81: 2964-2971.
47. Naundorf, S., M. Schröder, C. Höflich, N. Suman, H. D. Volk, and G. Grütz. 2009. IL-10 interferes directly with TCR-induced IFN-g but not IL-17 production in memory T cells. Eur. J. Immunol. 39: 1066-1077.
48. Tsitoura, D. C., R. H. DeKruyff, J. R. Lamb, and D. T. Umetsu. 1999. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J. Immunol. 163: 2592-2600.
49. + T cells. Immunobiology. 215: 163-171.
50. Sun, J. B., N. Cuburu, M. Blomquist, B. L. Li, C. Czerkinsky, and J. Holmgren. 2006. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand. J. Immunol. 64: 251-259.
51. Nashar, T. O., H. M. Webb, S. Eaglestone, N. A. Williams, and T. R. Hirst. 1996. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl. Acad. Sci. USA 93: 226-230.
52. Sun, J. B., S. Raghavan, A. Sjöling, S. Lundin, and J. Holmgren. 2006. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells. J. Immunol. 177: 7634-7644.
53. Sun, J. B., C. F. Flach, C. Czerkinsky, and J. Holmgren. 2008. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol. 181: 8278-8287.
54. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903.
55. Hasselberg, A., K. Schön, A. Tarkowski, and N. Lycke. 2009. Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. Arthritis Rheum. 60: 1672-1682.
56. Min, S. Y., K. S. Park, M. L. Cho, J. W. Kang, Y. G. Cho, S. Y. Hwang, M. J. Park, C. H. Yoon, J. K. Min, S. H. Lee, et al. 2006. Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum. 54: 887-898.
57. Hackstein, H., A. E. Morelli, and A. W. Thomson. 2001. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol. 22: 437-442.
58. Popov, I., M. Li, X. Zheng, H. San, X. Zhang, T. E. Ichim, M. Suzuki, B. Feng, C. Vladau, R. Zhong, et al. 2006. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res. Ther. 8: R141.
59. Charbonnier, L. M., L. M. van Duivenvoorde, F. Apparailly, C. Cantos, W. G. Han, D. Noël, C. Duperray, T. W. Huizinga, R. E. Toes, C. Jorgensen, and P. Louis-Plence. 2006. Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b+ regulatory T cells. J. Immunol. 177: 3806-3813.
60. Jaen, O., S. Rulle, N. Bessis, A. Zago, M. C. Boissier, and G. Falgarone. 2008. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology 126: 35-44.